• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

    2/25/25 7:00:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email

    Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch

    Presented groundbreaking XDEMVY data; first pharmacologic treatment to demonstrate functional improvements in Meibomian Gland Disease and patient symptoms in Demodex blepharitis patients

    Continued advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, the next category-creating opportunity in eye care

    Management to host conference call today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET

    IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2024, and recent business achievements.

    "Tarsus' demonstrated category-creating blueprint has established XDEMVY as one of the most successful eye care launches to date," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "We believe we are only beginning to unlock our full potential as the next leader in eye care and have so much to look forward to, including, potentially serving the millions of patients impacted by Demodex blepharitis, continuing to uncover new therapeutic indications and deepening our impact across eye care."

    Recent Business Highlights and Corporate Update

    • XDEMVY continued to be one of the fastest growing therapeutics in eye care.
      • Generated $66.4 million and $180.1 million in XDEMVY net product sales for the fourth quarter and full-year 2024, respectively.
      • Dispensed more than 58,500 and 163,000 bottles to patients in the fourth quarter and full-year 2024, respectively.

    • Established broad Eye Care Professional (ECP) utilization across more than 15,000 target ECPs.

    • The expanded sales force deployed in the third quarter started to deliver meaningfully to the increased ECP utilization and prescription volumes reported for the fourth quarter of 2024.

    • Broad commercial, Medicare and Medicaid reimbursement of XDEMVY now extends to more than 90% of covered lives, as of February 25, 2025.

      • Recognized a gross-to-net discount of approximately 45% in the fourth quarter and full-year 2024.
    • Activated a memorable and action-oriented Direct-To-Consumer (DTC) campaign on streaming platforms in the fourth quarter of 2024, and initiated a trial-run on network television in January 2025, including spots on the Golden Globes, the GRAMMYs and the National Football League playoffs.
      • The initial patient response from this campaign has been positive across multiple leading indicators, including the downloading of materials, taking the Demodex blepharitis (DB) quiz and utilizing the "find an eye doctor" tool on the XDEMVY website.
      • DTC to continue on streaming platforms and meaningfully expand into a network television campaign beginning in the first quarter of 2025.

    • Presented seminal data from the Ersa and Rhea clinical trials in DB patients with Meibomian Gland Disease (MGD) that underscore the benefit of XDEMVY broadly across multiple patient types, including functional improvements in:

      • Objective measures of MGD and the most common and impactful patient outcomes, including fluctuating vision.
    • Continued to advance a robust pipeline.
      • Pursuing the next potentially transformative category in eye care – Ocular Rosacea a highly prevalent and underserved eye disease with no FDA-approved therapy.
        • TP-04 is an investigational topical sterile ophthalmic gel formulation of lotilaner specifically designed for application across the eyelid and surrounding tissue.
        • Based on positive FDA feedback, the Company established a clear regulatory path forward for TP-04 and plans to initiate a Phase 2 study in the second half of 2025.
      • Planning to advance TP-05 for the potential prevention of Lyme disease.
        • TP-05 is an investigational oral tablet designed to kill ticks and potentially prevent Lyme disease transmission.
        • Based on positive engagements with the FDA, the Company has confirmed the planned regulatory path forward, which currently includes a Phase 2 study in hundreds of patients and a Phase 3 prevention study in thousands of patients.

    • Expanded and strengthened Tarsus' eye care leadership with two key appointments to the executive team and Board of Directors, respectively.

      • Elizabeth Yeu, M.D., was appointed Chief Medical Officer. Dr. Yeu is a distinguished ophthalmologist with more than two decades of experience, who transitioned from her previous role as Chief Medical Advisor and Board Member of Tarsus.
      • Katherine H. (Kate) Goodrich, M.D., MHS, joined the Company's Board of Directors. Dr. Goodrich is currently the Chief Medical Officer for Humana Inc., and brings decades of experience driving innovative and value-based initiatives designed to improve patient outcomes.

    Additional Potential Growth Drivers in 2025 and Beyond

    • On-track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027.
      • Initiated market development work, including Key Opinion Leader engagement, disease education and scientific presentations at major conferences.
    • In Japan, the Company expects to share results from a DB prevalence study in the first half of 2025, and meet with Japanese regulatory authorities to help determine a regulatory path forward.

    • The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application (NDA) submitted by Tarsus' partner, Grand Pharmaceutical Group Ltd., for TP-03 for DB.

    Fourth Quarter 2024 Financial Results

    • Product sales, net: were $66.4 million compared to $13.1 million for the same period in 2023, driven by approximately 58,500 bottles of XDEMVY dispensed to patients compared to approximately 15,700 bottles dispensed in the prior year period.
    • Cost of sales: were $4.9 million compared to $1.2 million for the same period in 2023, due to manufacturing costs incurred after the approval of XDEMVY, the royalty we pay on net product sales and the amortization of the approval milestones we paid to our licensor and are amortizing over a remaining 8.7 years.
    • Research and development (R&D) expenses: were $16.9 million in the fourth quarter compared to $13.3 million in the same period in 2023. The increase was primarily due to $2.5 million more in milestone expenses, $1.0 million of increased payroll and personnel-related costs (including non-cash stock-based compensation), and $1.0 million of increased program spend for TP-03, partially offset by $0.5 million less program spend on TP-05, $0.2 million less program spend on TP-04, and $0.2 million of decreased other indirect expenses. Total R&D non-cash stock-based compensation expense incurred was $1.8 million in the fourth quarter, compared with $1.5 million in the same period in 2023.
    • Selling, general and administrative (SG&A) expenses: were $69.0 million in the fourth quarter compared to $43.0 million in the same period in 2023. The increase was due primarily to $15.5 million of increased commercial and market research costs related to the commercial launch of XDEMVY, $7.8 million of increased payroll and personnel-related costs (including non-cash stock-based compensation), and $2.7 million of increased information technology, legal, professional and other corporate infrastructure. Total SG&A non-cash stock-based compensation expense incurred was $5.5 million in the fourth quarter, compared with $3.8 million in the same period in 2023.
    • Net loss: was $23.1 million, compared to $41.9 million for the same period in 2023. Basic and diluted net loss per share for the fourth quarter was $(0.60), compared with $(1.31) for the same period last year.
    • Cash position: As of December 31, 2024, cash, cash equivalents and marketable securities were $291.4 million.

    Full-Year 2024 Financial Results

    • Product sales, net: were $180.1 million compared to $14.7 million in the same period in 2023, driven by more than 163,000 bottles of XDEMVY dispensed to patients.
    • Cost of sales: were $12.8 million compared to $1.6 million for the same period in 2023, due to manufacturing costs incurred after the approval of XDEMVY, the royalty we pay on net product sales and the amortization of the approval milestone we paid to our licensor and are amortizing over a remaining 8.7 years.
    • R&D expenses: were $53.4 million in 2024 compared to $50.3 million in the same period in 2023. The increase was due to $3.5 million of increased payroll and personnel-related costs (including non-cash stock-based compensation), $1.5 million more in milestone expenses, $1.2 million of increased program spend for TP-03, and $0.7 million of increased other indirect expenses, partially offset by $2.7 million less program spend on TP-05, and $1.2 million less program spend on TP-04. Total R&D non-cash stock-based compensation expense incurred was $6.8 million in 2024, compared with $5.8 million in the same period in 2023.
    • SG&A expenses: were $237.3 million in 2024 compared to $108.7 million in the same period in 2023. The increase was due primarily to $52.0 million of increased commercial and marketing costs related to the commercial launch of XDEMVY, $39.7 million of increased payroll and personnel-related costs (including non-cash stock-based compensation), and $36.8 million of increased information technology, legal, professional and other corporate expenses. Total SG&A non-cash stock-based compensation expense incurred was $20.4 million in 2024, compared with $13.8 million in the same period in 2023.
    • Net loss: was $115.6 million, compared to $135.9 million for the same period in 2023. Basic and diluted net loss per share for 2024 was $(3.07), compared with $(4.62) for 2023.

    Conference Call and Webcast

    Tarsus will host a conference call and webcast to discuss its fourth quarter and full-year 2024 financial results and business highlights today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET. A live webcast will be available on the events section of the Tarsus website. A recorded version of the call will be available on the website shortly after the completion of the call and will be archived there for at least 90 days.

    About XDEMVY®

    XDEMVY (lotilaner ophthalmic solution, 0.25%), formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials collectively involving more than 800 patients. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.

    XDEMVY Indication and Important Safety Information

    INDICATIONS AND USAGE

    XDEMVY is indicated for the treatment of Demodex blepharitis.

    Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

    For additional information, please see full prescribing information available at: https://xdemvy.com/.

    About TP-04

    TP-04 is an investigational aqueous gel formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills mites by selectively inhibiting parasite-specific GABA-Cl channels. Tarsus is studying TP-04 for the potential treatment of Ocular Rosacea.

    About TP-05

    TP-05 is an investigational oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission.

    About Tarsus Pharmaceuticals, Inc.

    Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

    Forward-Looking Statements

    Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including market size, acceptance, demand, and adoption rate for XDEMVY; our ability to achieve and maintain distribution and patient access for XDEMVY and timing and breadth of payer coverage; our ability to successfully implement our sales force expansion and new direct-to-consumer campaign including network television; our ability to continue to educate the market about Demodex blepharitis, the timing, objectives, and results of the clinical trials including planned initiation of Phase 2 trials for the potential treatment of Ocular Rosacea and the prevention of Lyme disease, the potential market size, opportunity, and ECP education for Ocular Rosacea and our other pipeline indications, anticipated regulatory and development milestones including the clarity of the regulatory path forward for TP-04 and TP-05 in the U.S., and potential Europe, Japan, and China regulatory pathways and approval for XDEMVY, the potential benefits of the new executive and board member, our ability to continue investing in our business and become an eye care leader, and the quotations of Tarsus' management. The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus is heavily dependent on the successful commercialization of its lead product, XDEMVY for the treatment of Demodex blepharitis and the development and regulatory approval and commercialization of its current and future product candidates; Tarsus' ability to obtain and maintain regulatory approval for and successfully commercialize its products, including XDEMVY for the treatment of Demodex blepharitis, and its product candidates to meet existing and future regulatory standards; Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus' capital requirements are difficult to predict and may change; Tarsus may need to obtain additional funding to achieve its goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force Tarsus to delay, reduce or eliminate its product development programs, commercialization efforts or other operations; Tarsus may not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis and other diseases targeted by XDEMVY or our product candidates; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus expects to expand its development, regulatory, operational and sales and marketing capabilities and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for XDEMVY and Tarsus' product candidates, particularly TP-04 for the potential treatment of Ocular Rosacea, as well as TP-05 for the potential prevention of Lyme disease, have not been established with precision and may be smaller than estimated; the results of Tarsus' earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus' planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus' competitors could develop and commercialize products similar or identical to Tarsus' products; and if Tarsus is unable to access capital (including but not limited to cash, cash equivalents, and credit facilities) and/or loses capital, as a result of potential failure of any financial institutions that Tarsus does business with directly or indirectly. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statements and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus' Form 10-K for the year ended December 31, 2024 planned to be filed on February 25, 2025, which Tarsus incorporates by reference into this press release, copies of which are or will be posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Media Contact:

    Adrienne Kemp

    Sr. Director, Corporate Communications

    (949) 922-0801

    [email protected]

    Investor Contact:

    David Nakasone

    Head of Investor Relations

    (949) 620-3223

    [email protected]

    TARSUS PHARMACEUTICALS, INC.
     
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (In thousands, except share and per share amounts)
        
     Three Months Ended

    December 31,
     Year Ended

    December 31,
     2024

     2023

     2024

     2023

    Revenues:       
    Product sales, net$66,408  $13,076  $180,059  $14,729 
    License fees and collaboration revenue —   —   2,894   2,718 
    Total revenues 66,408   13,076   182,953   17,447 
    Operating expenses:       
    Cost of sales 4,926   1,216   12,826   1,593 
    Cost of license fees and collaboration revenue —   —   —   — 
    Research and development 16,873   13,305   53,386   50,312 
    Selling, general and administrative 69,030   43,005   237,310   108,700 
    Total operating expenses 90,829   57,526   303,522   160,605 
    Loss from operations (24,421)  (44,450)  (120,569)  (143,158)
    Other income (expense):       
    Interest income 3,647   2,978   15,014   10,337 
    Interest expense (2,312)  (989)  (7,849)  (3,346)
    Loss on debt extinguishment —   —   (1,944)  — 
    Other income (expense), net (27)  (13)  586   (102)
    Realized/unrealized (loss) gain on equity investments —   420   (591)  259 
    Change in fair value of equity warrants issued by licensee —   152   (201)  117 
    Total other income, net 1,308   2,548   5,015   7,265 
    Net loss$(23,113) $(41,902) $(115,554) $(135,893)
            
    Unrealized gain (loss) on marketable securities and cash equivalents (167)  6   181   72 
    Comprehensive loss$(23,280) $(41,896) $(115,373) $(135,821)
            
    Net loss per share, basic and diluted$(0.60) $(1.31) $(3.07) $(4.62)
    Weighted-average shares outstanding, basic and diluted 38,560,907   31,944,237   37,604,538   29,383,276 



    TARSUS PHARMACEUTICALS, INC.
     
    BALANCE SHEETS
    (In thousands, except share and par value amounts)
      
     December 31,
      2024   2023 
    ASSETS   
    Current assets:   
    Cash and cash equivalents$94,819  $224,947 
    Marketable securities 196,557   2,495 
    Accounts receivable, net 46,760   16,621 
    Inventory 2,620   3,107 
    Other receivables 1,299   1,093 
    Prepaid expenses 14,650   7,868 
    Total current assets 356,705   256,131 
    Restricted cash, non-current 2,562   — 
    Inventory, non-current 2,533   — 
    Property and equipment, net 2,314   1,468 
    Intangible assets, net 8,326   3,867 
    Operating lease right-of-use assets 552   1,880 
    Long-term investments 3,000   631 
    Other assets 999   1,514 
    Total assets$376,991  $265,491 
    LIABILITIES AND STOCKHOLDERS' EQUITY   
    Current liabilities:   
    Accounts payable and other accrued liabilities$64,789  $23,691 
    Accrued payroll and benefits 15,823   13,245 
    Total current liabilities 80,612   36,936 
    Long-term debt, net 71,845   29,819 
    Other long-term liabilities —   1,748 
    Total liabilities 152,457   68,503 
    Commitments and contingencies   
    Stockholders' equity:   
    Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding —   — 
    Common stock, $0.0001 par value; 200,000,000 shares authorized; 38,349,826 shares issued and outstanding at December 31, 2024; 34,211,190 shares issued and outstanding at December 31, 2023 6   5 
    Additional paid-in capital 584,559   441,641 
    Accumulated other comprehensive income (loss) 179   (2)
    Accumulated deficit (360,210)  (244,656)
    Total stockholders' equity 224,534   196,988 
    Total liabilities and stockholders' equity$376,991  $265,491 


    Primary Logo

    Get the next $TARS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    8/1/2022$40.00Overweight
    Barclays
    12/21/2021$40.00Buy
    HC Wainwright & Co.
    11/23/2021$55.00Outperform
    Oppenheimer
    10/8/2021$50.00 → $65.00Strong Buy
    Raymond James
    6/29/2021$39.00 → $50.00Strong Buy
    Raymond James
    More analyst ratings

    $TARS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tarsus to Participate in Upcoming Investor Conferences

      IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20th, at 12:00 p.m. PT / 3:00 p.m. ETStifel Virtual Ophthalmology Forum on Tuesday, May 27th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours a

      5/8/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO and Board Chair Azamian Bobak R. sold $300,000 worth of shares (6,000 units at $50.00) (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/26/25 4:47:19 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Mottiwala Aziz sold $505,856 worth of shares (10,565 units at $47.88), decreasing direct ownership by 14% to 65,057 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:54 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Neervannan Seshadri sold $363,142 worth of shares (7,583 units at $47.89), decreasing direct ownership by 9% to 79,682 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tarsus Pharmaceuticals with a new price target

      Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00

      11/20/23 7:55:38 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Tarsus Pharmaceuticals with a new price target

      William Blair initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $44.00

      7/18/23 7:27:56 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Tarsus Pharmaceuticals

      Guggenheim initiated coverage of Tarsus Pharmaceuticals with a rating of Buy

      5/18/23 7:36:58 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      12/19/23 6:30:59 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

      Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:29:16 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Leadership Updates

    Live Leadership Updates

    See more
    • Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

      Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access

      11/13/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

      IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris

      11/5/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

      IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra

      4/24/23 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Financials

    Live finance-specific insights

    See more
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad

      4/24/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

      Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; first pharmacologic treatment to demonstrate functional improvements in Meibomian Gland Disease and patient symptoms in Demodex blepharitis patients Continued advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, the next category-creating opportunity in eye care Management to host conference call today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced

      2/25/25 7:00:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

      SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:41:12 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:35:55 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 3:05:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      5/7/25 11:27:44 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.

      10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

      5/1/25 4:10:36 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

      5/1/25 4:07:27 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care